Entyvio Continues to Show Benefits for Inflammatory Bowel Disease
A promising future for data
Mona Khalid, the senior director and head of evidence and value generation at Takeda said that, “These data provide additional insight on the usage patterns, long-term safety profile and outcomes of Entyvio use in real-world clinical practice. We look forward to the continued expansion of our body of knowledge on the safety profile of Entyvio treatment in ulcerative colitis and Crohn’s disease.” Other studies about vedolizumab were also presented at UEG week.
